How to Fight Insurance Denials for Eating Disorder Treatment

Eating disorders—anorexia nervosa (AN), bulimia nervosa (BN), binge eating disorder (BED), and avoidant/restrictive food intake disorder (ARFID)—require intensive, specialized treatment at the right level of care. Yet insurers routinely deny coverage for residential programs, partial hospitalization (PHP), and intensive outpatient (IOP) care, often using proprietary internal criteria like MCG or InterQual guidelines that don't align with current medical standards. These denials frequently violate the federal Mental Health Parity and Addiction Equity Act (MHPAEA), which requires insurers to cover mental health and eating disorder treatment with the same rigor they apply to medical care. The 2019 landmark ruling Wit v. United Behavioral Health found that UnitedHealthcare's internal criteria systematically deviated from generally accepted standards of care, establishing a powerful legal precedent. If you've received a denial, understanding the specific clinical guidelines insurers are legally required to follow—and how to argue against common denial templates—can make the difference between getting care and facing medical crisis.

Why Insurers Deny Eating Disorder Treatment

Insurers use a handful of stock denial reasons that often ignore the severity of eating disorders and the continuum-of-care model endorsed by medical experts:

1. "Not medically necessary at this level of care"

The most common denial. Insurers claim you can be treated safely at a lower level—outpatient therapy instead of IOP, IOP instead of PHP, PHP instead of residential—using arbitrary internal thresholds (like BMI cutoffs or vital-sign criteria) that don't reflect the full clinical picture. These thresholds often come from MCG or InterQual, proprietary guidelines that many clinicians argue are too restrictive and outdated.

2. "Failed to demonstrate medical stabilization need"

For residential or inpatient denials, insurers may claim that because you're not currently experiencing acute cardiac instability, severe electrolyte derangement, or life-threatening complications right now, you don't need 24-hour care. This ignores the progressive nature of eating disorders and the fact that residential treatment addresses psychological and behavioral severity, not just medical crises.

3. "Insufficient prior treatment at lower level of care"

Insurers argue you haven't "failed" outpatient or IOP treatment yet, so stepping up to a higher level isn't justified. This creates dangerous delays: patients are forced to deteriorate further while cycling through inadequate care, even when their treatment team has determined a higher level is clinically appropriate now.

4. "Experimental or investigational treatment"

For specific therapies like Family-Based Treatment (FBT) for adolescent anorexia, Enhanced CBT (CBT-E), Dialectical Behavior Therapy (DBT), or medications like olanzapine for weight restoration in AN or Vyvanse for binge eating disorder, insurers may claim the treatment lacks sufficient evidence. In reality, these interventions are supported by robust clinical guidelines and research.

5. "Out-of-network / not contracted provider"

Even when insurers acknowledge medical necessity, they may deny coverage because your treatment program isn't in-network, claiming adequate in-network alternatives exist. For eating disorders, many regions have few or no in-network residential or PHP programs with specialized expertise, making this a parity violation when the insurer would cover out-of-network care for a comparable medical condition.

The Citations Insurers Must Respect

When you appeal, reference these specific authoritative sources—insurers are legally required to defer to generally accepted standards of care, not their own internal rules:

American Psychiatric Association (APA) Practice Guideline for the Treatment of Patients With Eating Disorders, 4th Edition (2023)

The gold standard clinical guideline. It outlines criteria for each level of care (inpatient medical, residential, PHP, IOP, outpatient) based on medical status, psychological severity, comorbidities, motivation, and prior treatment response—not just BMI or vital signs. APA 2023 emphasizes individualized treatment planning and explicitly supports higher levels of care for patients with functional impairment, suicidality, or inadequate response to lower levels.

Academy for Eating Disorders (AED) Medical Care Standards, 9th Edition

Internationally recognized standards detailing medical complications and criteria for hospitalization, including specific vital-sign and laboratory thresholds (e.g., heart rate <50 bpm daytime or <45 bpm nighttime, orthostatic blood pressure changes, electrolyte abnormalities, refeeding syndrome risk). AED standards make clear that medical stabilization is just one component of treatment; psychological and behavioral factors also dictate level of care.

Mental Health Parity and Addiction Equity Act (MHPAEA, 2008) and DOL/HHS guidance (2013, 2021 updates)

Federal law requiring that mental health and substance use disorder benefits—including eating disorder treatment—be covered on par with medical/surgical benefits. Insurers cannot apply stricter prior authorization, narrower networks, or more restrictive medical-necessity criteria to behavioral health than they do to medical care. The 2021 Consolidated Appropriations Act strengthened enforcement, requiring insurers to conduct comparative analyses proving parity compliance.

Wit v. United Behavioral Health, N.D. Cal. Case No. 14-cv-02346-JCS (2019)

A class-action ruling that found UnitedHealthcare's internal guidelines systematically undervalued accepted standards of care, improperly emphasizing acute stabilization over functional improvement and relapse prevention. The court held that insurers must use "generally accepted standards of care" developed by independent medical organizations (like APA and AED), not cost-driven internal criteria. This precedent applies beyond UnitedHealthcare and is cited in appeals against all major insurers.

Fluoxetine (Prozac) for Bulimia Nervosa—FDA approval 1994, APA 2023 endorsed

Fluoxetine 60 mg/day is the only FDA-approved medication for bulimia nervosa and is first-line pharmacotherapy per APA 2023.

Vyvanse (lisdexamfetamine) for Binge Eating Disorder—FDA approval 2015, NEJM trial McElroy et al. 2015

The only FDA-approved medication for moderate-to-severe BED, supported by randomized controlled trials showing significant reduction in binge days.

Olanzapine for Anorexia Nervosa weight restoration—Attia et al. 2019 meta-analysis, APA 2023 recognized

Off-label use of low-dose olanzapine (2.5–10 mg/day) to facilitate weight gain in AN is supported by multiple trials and endorsed in APA 2023 as an adjunct to nutritional rehabilitation.

Family-Based Treatment (FBT / Maudsley Method) for Adolescent AN—Lock & Le Grange, multiple RCTs 2010–2019, AAP Clinical Report 2021

Evidence-based first-line treatment for adolescents with AN, endorsed by the American Academy of Pediatrics. FBT has the strongest evidence base for adolescent eating disorders.

Enhanced Cognitive Behavioral Therapy (CBT-E)—Fairburn et al., Behaviour Research and Therapy 2009; Cooper & Fairburn meta-analysis 2011

Transdiagnostic treatment for adult eating disorders (AN, BN, BED, OSFED) with robust outcomes across multiple trials.

How to Argue Against Each Common Denial Reason

1. "Not medically necessary at this level of care"

Concrete steps:

• Cite APA 2023 and AED 9th edition criteria for your recommended level of care. Don't let the insurer rely solely on BMI or vital signs. The APA emphasizes a multidimensional assessment: medical complications, suicidality, motivation for recovery, environmental stress, comorbid psychiatric conditions, prior treatment response, and ability to care for oneself. Spell out how your situation meets multiple APA criteria for the denied level.

• Document functional impairment. APA 2023 explicitly includes "impairment in role functioning" (school, work, family relationships) as a criterion for higher levels of care. Detail days missed from school or work, inability to eat with family, hours per day consumed by rituals (body checking, calorie counting, compulsive exercise), social withdrawal, loss of relationships. Functional impairment is as medically relevant as vital signs.

• Include vitals and labs if abnormal, but don't stop there. If you have bradycardia (heart rate <50 daytime per AED), orthostatic hypotension, electrolyte abnormalities (potassium <3.2, phosphorus <2.5, magnesium low), or EKG changes (prolonged QTc), highlight them. But also explain why waiting for a full medical crisis is dangerous: eating disorders are progressive, and early intensive intervention prevents mortality and morbidity.

• Invoke Wit v. UBH. Explain that the court found UBH's reliance on "acute" criteria unlawful because generally accepted standards (APA, AED) require considering relapse prevention, functional recovery, and family/social factors—not just immediate medical danger. Your insurer's internal criteria likely repeat this error.

• Use your treatment team's letter. A detailed letter from your psychiatrist, psychologist, physician, or program medical director—citing APA 2023 and AED by name and explaining why lower levels have failed or are inadequate—is your most powerful tool. The letter should address each of the insurer's stated reasons and map your clinical presentation to published criteria.

Example argument:

"The denial states I do not meet criteria for residential treatment because my BMI is 16.2 and my vital signs are 'stable.' However, the APA 2023 Practice Guideline (Section 4.2.3) specifies that residential care is appropriate when outpatient and IOP have been insufficient to achieve progress, when there is high suicidality or self-injury risk, or when family environment is unable to support recovery. I completed 6 weeks of IOP (March 15–April 26) and lost 4 pounds, my restriction worsened, and I am now missing 4 days per week of school due to anxiety and ritualistic eating behaviors. AED 9th edition notes that bradycardia <50 bpm (mine is 46–48 daytime) and orthostatic BP changes (I have a 22-point systolic drop) indicate medical risk requiring close monitoring. Residential treatment addresses both the medical and psychological severity that lower levels cannot manage. Denying this based on proprietary MCG criteria directly conflicts with generally accepted standards and violates the holding in Wit v. UBH."

---

2. "Failed to demonstrate medical stabilization need"

Concrete steps:

• Clarify that residential and PHP are not just for acute medical crises. APA 2023 explicitly states that residential treatment is indicated for patients who require 24-hour structured support for meal supervision, interruption of behaviors (purging, excessive exercise), and intensive therapy—not only those in cardiac failure. Insurers often conflate "residential" with "inpatient hospital," but these are distinct levels of care with different purposes.

• Emphasize refeeding syndrome risk. If you have a history of severe restriction, low BMI, and are beginning nutritional rehabilitation, the risk of refeeding syndrome (potentially fatal shifts in electrolytes when reintroducing food) requires close medical monitoring. AED standards detail refeeding protocols that necessitate frequent labs and physician oversight, justifying residential or PHP with robust medical staffing.

• Highlight comorbidities. Depression, anxiety, OCD, PTSD, or substance use disorders are common in eating disorders and complicate treatment. MHPAEA requires insurers to consider the whole person. If you have active suicidality or self-injury, this alone can justify 24-hour care even if your vital signs are currently "stable."

• Point to treatment failure at lower levels. If you've tried outpatient or IOP and continued to lose weight, escalate behaviors, or experience worsening mood, document this as evidence that less intensive care is insufficient. APA 2023 treats prior treatment response as a key decision factor.

Example argument:

"The denial asserts I do not require residential care because I am 'medically stable.' However, APA 2023 defines residential treatment as appropriate for individuals who need 24-hour supervision to interrupt eating-disorder behaviors and manage meals—not only those in acute cardiac crisis (see APA 2023 Table 2, Level of Care Criteria). I am currently consuming fewer than 800 calories per day, have lost 18% of my body weight in 4 months, and my labs show potassium 3.1 and phosphorus 2.3—both indicative of malnutrition and refeeding risk per AED standards. My treatment team has recommended residential placement to safely renourish under medical monitoring and to provide the structured, multidisciplinary therapy (CBT-E, family therapy, meal support) that I cannot access at home or in weekly outpatient sessions. Requiring me to wait for a cardiac emergency before approving this care is inconsistent with the preventive, recovery-oriented approach endorsed by APA and AED."

---

3. "Insufficient prior treatment at lower level of care"

Concrete steps:

• Challenge the "fail first" policy as a parity violation. Would the insurer require a cancer patient to try an inadequate chemotherapy protocol and fail before approving the oncologist-recommended treatment? Probably not. MHPAEA prohibits applying stricter step-therapy or "fail-first" requirements to behavioral health than to medical care. Cite this explicitly.

• Document the risks of delay. Eating disorders have the highest mortality rate of any psychiatric illness. Forcing a patient to deteriorate further at an inadequate level of care increases risk of cardiac events, suicide, and chronic illness. Include literature or provider statements on mortality and morbidity.

• Show prior treatment was inadequate, not that it "failed." If you did try a lower level but it lacked specialized eating-disorder expertise (e.g., a general therapist rather than an ED specialist, or an IOP without meal support and dietitian involvement), explain that APA 2023 emphasizes evidence-based, specialized treatment. Inadequate treatment doesn't count as a true trial.

• Adolescents and first-episode patients may not need prior failures. APA 2023 and AAP 2021 note that for adolescents, early intensive intervention—particularly FBT or higher levels of care—can prevent chronicity. Insurers cannot impose adult fail-first logic on pediatric cases.

Example argument:

"The denial states I must 'fail' IOP before residential is approved. However, my treatment team has determined that IOP is clinically inappropriate given my current severity: BMI 14.9 (extreme severity per DSM-5), heart rate in the 30s at night, suicidal ideation with plan, and inability to complete meals even with family supervision. Requiring me to enroll in IOP—where I would attend a few hours per day but return home to an environment where I cannot maintain safety or nutrition—would delay necessary care and increase medical risk. The federal parity law prohibits imposing fail-first requirements on mental health treatment that would not be applied to comparable medical conditions. If I had severe diabetic ketoacidosis, my insurer would not require me to 'fail' outpatient management before covering hospitalization. The same standard applies here under MHPAEA. Additionally, Wit v. UBH held that requiring patients to deteriorate before stepping up care conflicts with generally accepted standards focused on recovery and prevention."

---

4. "Experimental or investigational treatment"

Concrete steps:

• Cite FDA approval (for medications). Fluoxetine for BN and Vyvanse for BED are FDA-approved and cannot be denied as experimental. Olanzapine for AN is off-label but widely endorsed (APA 2023, multiple peer-reviewed trials).

• Cite APA 2023 and evidence base (for therapies). FBT for adolescent AN, CBT-E for adults, DBT for comorbid BED and borderline personality, and CBT-AR for ARFID all have strong evidence bases and are explicitly recommended in APA 2023. Include trial citations if available (e.g., Lock & Le Grange for FBT, Fairburn et al. for CBT-E, Thomas & Eddy for CBT-AR).

• Highlight that evidence-based doesn't mean universally covered in-network. Insurers may conflate "not commonly available in our network" with "experimental." Point out that lack of in-network specialized providers doesn't render the treatment investigational—it's a network adequacy problem and a potential parity violation.

Example argument:

"The denial claims Family-Based Treatment (FBT) for my adolescent daughter's anorexia nervosa is investigational. This is incorrect. FBT (also called the Maudsley Method) is the first-line treatment for adolescent AN per the APA 2023 Practice Guideline and the AAP 2021 Clinical Report on Eating Disorders in Adolescents. It is supported by multiple randomized controlled trials (Lock et al. 2010; Le Grange et al. 2014) showing superior outcomes to individual therapy. Denying coverage for the evidence-based standard of care while offering only generic outpatient therapy violates both generally accepted standards and MHPAEA, which requires coverage of the most effective treatments for behavioral health conditions."

---

5. "Out-of-network / not contracted provider"

Concrete steps:

• Request a network adequacy review. Ask the insurer to identify in-network residential, PHP, or specialized ED programs within a reasonable distance (typically <50 miles or 30 minutes) that have availability, treat your specific diagnosis and age group, and offer evidence-based therapies. If they cannot, they must cover out-of-network care at in-network rates as a "gap exception."

• Cite MHPAEA network adequacy standards. Federal regulations (and many state laws) require insurers to maintain behavioral health networks comparable to their medical networks. If eating disorder specialty networks are narrower than, say, cardiology or oncology networks, that's a parity violation.

• Provide evidence of specialized need. Eating disorders require multidisciplinary teams (psychiatrist, psychologist, dietitian, medical physician), evidence-based protocols (e.g., APA 2023, AED refeeding guidelines), and specialized training. A general mental health facility or therapist may not meet this standard, justifying out-of-network care at an ED specialty program.

• Document urgency. If your medical or psychological condition is deteriorating and the insurer's delay in finding in-network care is harmful, state this explicitly and request expedited authorization.

Example argument:

"The denial states that I must use an in-network PHP program. However, the insurer has not identified any in-network PHP with eating-disorder specialization within 100 miles of my home. The general mental health PHP the insurer suggested does not employ a dietitian, does not provide meal support, and does not follow APA 2023 or AED guidelines for eating disorder treatment. Under MHPAEA and state network adequacy laws, the insurer must provide access to specialized care comparable to what it provides for medical conditions. I request a gap exception authorizing [out-of-network ED program name] at in-network rates, as this is the closest program with specialized ED expertise and availability. My treatment team's letter explains why general mental health care is clinically inadequate for anorexia nervosa."

---

What We Do

We turn your clinical story, treatment records, and the insurer's denial into a comprehensive appeal that meets health plans at their level—complete with policy citations, case law, and the guidelines they're required to follow under federal parity law. We work with your treatment team to translate their clinical judgment into the language of medical necessity, APA and AED criteria, and the Wit v. UBH legal standard. Every appeal we write is tailored to your case, your insurer, and the specific denial reason, giving you the strongest possible argument to get your care approved.

---

Sources

1. American Psychiatric Association. (2023). Practice Guideline for the Treatment of Patients With Eating Disorders (4th ed.). Washington, DC: APA.

2. Academy for Eating Disorders. Medical Care Standards Guide (9th ed.). https://www.aedweb.org/publications/medical-care-standards

3. Mental Health Parity and Addiction Equity Act of 2008, 29 U.S.C. § 1185a; 42 U.S.C. § 300gg-26.

4. U.S. Departments of Labor, Health and Human Services, and Treasury. (2013, 2021). Mental Health Parity and Addiction Equity Act Compliance Guidance.

5. Wit v. United Behavioral Health, No. 14-cv-02346-JCS, 2019 WL 1033730 (N.D. Cal. Mar. 5, 2019).

6. U.S. Food and Drug Administration. (1994). Fluoxetine approval for bulimia nervosa. (2015). Lisdexamfetamine approval for binge eating disorder.

7. McElroy, S. L., et al. (2015). Lisdexamfetamine dimesylate for adults with moderate to severe binge eating disorder: Results of two pivotal phase 3 randomized controlled trials. Neuropsychopharmacology, 40(5), 1448–1456.

8. Attia, E., et al. (2019). Olanzapine versus placebo for outpatients with anorexia nervosa: A meta-analysis. Psychological Medicine, 49(13), 2317–2325.

9. Lock, J., & Le Grange, D. (2019). Family-based treatment: Where are we and where should we be going to improve recovery in child and adolescent eating disorders. International Journal of Eating Disorders, 52(4), 481–487.

10. American Academy of Pediatrics, Committee on Adolescence, Golden, N. H., et al. (2021). Preventing obesity and eating disorders in adolescents. Pediatrics, 147(1), e2020040279.

11. Fairburn, C. G., et al. (2009). Transdiagnostic cognitive-behavioral therapy for patients with eating disorders: A two-site trial with 60-week follow-up. American Journal of Psychiatry, 166(3), 311–319.

12. Thomas, J. J., & Eddy, K. T. (2019). Cognitive-Behavioral Therapy for Avoidant/Restrictive Food Intake Disorder: Children, Adolescents, and Adults. Cambridge University Press.

13. National Eating Disorders Association & Deloitte Access Economics. (2020). The Social and Economic Cost of Eating Disorders in the United States.